Learn More
BACKGROUND Eribulin mesylate is a synthetic macrocyclic ketone analogue of Halichondrin B that has demonstrated high antitumor activity in preclinical and clinical settings. This phase I study aimed to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics in combination with cisplatin (CP) in patients with(More)
PURPOSE The primary objective was to determine the maximum tolerated doses (MTDs) of the combination of bortezomib and temozolomide in patients with solid tumors. The secondary objective was to evaluate the pharmacokinetics (PK) of bortezomib with and without concurrent hepatic enzyme-inducing anticonvulsants (HEIAs). METHODS Bortezomib was administered(More)
5563 Background: Conventional dosing of C (400 mg/m2 loading dose, 250 mg/m2 weekly) yields response rate of approximately 13% among pts with R/M HNSCC. Conventional weekly dosing of C may not saturate EGFR adequately (Clin Cancer Res 7:1204), and can be inconvenient for pts. C can safely be administered every 2 weeks (Q2W) at high doses (between 400 and(More)
5617 Background: NCT with radiation has facilitated organ-sparing treatment in locally advanced SCHNC. We conducted a phase II study of patients (pts) with SCHNC to evaluate a combination of NCT, radiation, and surgery to evaluate response to NCT as well as evaluate overall survival and recurrence patterns. METHODS Pts had resectable untreated stage III,(More)
BACKGROUND Adenoid cystic carcinoma (ACC) is a subtype of malignant salivary gland tumors (MSGT), in which 90% of cases express cKIT. Dasatinib is a potent and selective inhibitor of five oncogenic protein tyrosine kinases (PTKs)/kinase families including cKIT. We conducted a phase II study to determine the antitumor activity of dasatinib in ACC and non-ACC(More)
12004 Background: Bortezomib (B) and topotecan (T) have been shown in pre-clinical testing to be synergistic. Based on this data we have performed a phase I study to determine the maximally tolerated dose and toxicities (tox) of B and T delivered sequentially. METHODS 24 pts (KPS<ECOG 3) with advanced malignancies were treated with T (2.0, 2.5, 3.0 or 3.5(More)
609 Background: Adjuvant chemotherapy is recommended after rectal cancer surgery. Yet the success and complication rates of this adjuvant treatment are poorly studied. The purpose of this study is to determine the success rate and define the toxicity profile of adjuvant chemotherapy in rectal cancer patients previously treated with neoadjuvant chemotherapy.(More)